In last trading session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw 0.47 million shares changing hands with its beta currently measuring 1.60. Company’s recent per share price level of $8.85 trading at $0.84 or 10.49% at ring of the bell on the day assigns it a market valuation of $460.91M. That closing price of EYPT’s stock is at a discount of -250.17% from its 52-week high price of $30.99 and is indicating a premium of 35.93% from its 52-week low price of $5.67. Taking a look at company’s average trading volume volume of 1.15 million if we extend that period to 3-months.
For EyePoint Pharmaceuticals Inc (EYPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.52 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Upright in the green during last session for gaining 10.49%, in the last five days EYPT remained trading in the green while hitting it’s week-highest on Friday, 06/28/24 when the stock touched $8.85 price level, adding 4.22% to its value on the day. EyePoint Pharmaceuticals Inc’s shares saw a change of -61.70% in year-to-date performance and have moved 8.06% in past 5-day. EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) showed a performance of -10.43% in past 30-days.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 70.5% to its current value. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -238.98% in reaching the projected high whereas dropping to the targeted low would mean a loss of -238.98% for stock’s current value.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Statistics highlight that EyePoint Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -60.70% of value to its shares in past 6 months, showing an annual growth rate of -21.98% while that of industry is 15.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -14.60% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.59M for the same. And 9 analysts are in estimates of company making revenue of 9.26M in the next quarter. Company posted 9.11M and 15.2M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.57% during past 5 years.
EYPT Dividends
EyePoint Pharmaceuticals Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
Insiders are in possession of 1.41% of company’s total shares while institution are holding 110.96 percent of that, with stock having share float percentage of 112.54% . Investors also watch the number of corporate investors in a company very closely, which is 110.96% institutions for EyePoint Pharmaceuticals Inc that are currently holding shares of the company. Cormorant Asset Management, LP is the top institutional holder at EYPT for having 6.89 shares of worth $59.42 million. And as of Mar 31, 2024 , it was holding 13.23% of the company’s outstanding shares.
The second largest institutional holder is Adage Capital Partners GP L.L.C. , which was holding about 4.76 shares on Mar 31, 2024 . The number of shares represents firm’s hold over 9.13% of outstanding shares, having a total worth of $41.0 million.
On the other hand, Franklin Strategic Series-Franklin Small Cap Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2024 , the former fund manager was holding 1.58 shares of worth $13.59 million or 3.03% of the total outstanding shares. The later fund manager was in possession of 1.49 shares on Mar 31, 2024 , making its stake of worth around $12.82 million in the company or a holder of 2.86% of company’s stock.
